Skip to Content

Anidulafungin Pregnancy and Breastfeeding Warnings

Anidulafungin is also known as: Eraxis

Medically reviewed on March 7, 2018

Anidulafungin Pregnancy Warnings

Anidulafungin has been assigned to pregnancy category B by the FDA. Animal studies have revealed evidence of fetotoxicity. In rats, anidulafungin crossed the placental barrier, was detected in fetal plasma, and was associated with incomplete ossification of several bones. There are no controlled data in human pregnancy. Anidulafungin is only recommended for use during pregnancy when benefit outweighs risk.

See references

Anidulafungin Breastfeeding Warnings

There are no data on the excretion of anidulafungin into human milk. Anidulafungin was found in the milk of lactating rats. The manufacturer recommends that caution be used when administering anidulafungin to nursing women.

See references

References for pregnancy information

  1. "Product Information. Eraxis (anidulafungin)." Pfizer U.S. Pharmaceuticals Group, New York, NY.

References for breastfeeding information

  1. "Product Information. Eraxis (anidulafungin)." Pfizer U.S. Pharmaceuticals Group, New York, NY.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Hide